AtriCure, Inc. (NASDAQ:ATRC) Insider Sells $36,135.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Justin J. Noznesky sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $24.09, for a total value of $36,135.00. Following the transaction, the insider now owns 71,284 shares of the company’s stock, valued at $1,717,231.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AtriCure Stock Performance

NASDAQ ATRC opened at $20.89 on Monday. AtriCure, Inc. has a twelve month low of $20.19 and a twelve month high of $59.61. The company has a quick ratio of 2.66, a current ratio of 3.57 and a debt-to-equity ratio of 0.15. The stock has a market cap of $994.16 million, a P/E ratio of -26.11 and a beta of 1.41. The company’s 50-day simple moving average is $28.81 and its 200 day simple moving average is $33.09.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). AtriCure had a negative net margin of 8.98% and a negative return on equity of 7.82%. The company had revenue of $108.90 million for the quarter, compared to analyst estimates of $106.86 million. During the same period in the previous year, the firm posted ($0.23) earnings per share. The firm’s revenue for the quarter was up 16.5% compared to the same quarter last year. As a group, research analysts forecast that AtriCure, Inc. will post -0.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

ATRC has been the topic of a number of research reports. UBS Group boosted their target price on shares of AtriCure from $57.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. Canaccord Genuity Group dropped their price objective on shares of AtriCure from $57.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday. Needham & Company LLC reduced their target price on shares of AtriCure from $46.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday. Stifel Nicolaus decreased their target price on AtriCure from $50.00 to $42.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Finally, StockNews.com cut AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, AtriCure has an average rating of “Moderate Buy” and an average target price of $49.78.

Institutional Trading of AtriCure

A number of large investors have recently bought and sold shares of ATRC. RiverPark Advisors LLC bought a new position in shares of AtriCure during the third quarter valued at $27,000. Allspring Global Investments Holdings LLC grew its holdings in shares of AtriCure by 31.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,074 shares of the medical device company’s stock worth $91,000 after purchasing an additional 497 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of AtriCure during the 4th quarter worth about $103,000. Virtu Financial LLC bought a new position in AtriCure during the 4th quarter valued at about $213,000. Finally, Victory Capital Management Inc. lifted its holdings in AtriCure by 22.9% during the 4th quarter. Victory Capital Management Inc. now owns 6,202 shares of the medical device company’s stock valued at $221,000 after purchasing an additional 1,155 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.